Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.26 USD | +1.62% | +19.01% | -30.37% |
Financials (USD)
Sales 2024 * | 216M | Sales 2025 * | 302M | Capitalization | 476M |
---|---|---|---|---|---|
Net income 2024 * | -238M | Net income 2025 * | -164M | EV / Sales 2024 * | 2.76 x |
Net Debt 2024 * | 118M | Net Debt 2025 * | 69.33M | EV / Sales 2025 * | 1.81 x |
P/E ratio 2024 * |
-2.09
x | P/E ratio 2025 * |
-3.33
x | Employees | 380 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.81% |
Latest transcript on Travere Therapeutics, Inc.
1 day | +1.62% | ||
1 week | +19.01% | ||
Current month | +13.20% | ||
1 month | -11.08% | ||
3 months | -24.21% | ||
6 months | -10.19% | ||
Current year | -30.37% |
Managers | Title | Age | Since |
---|---|---|---|
Eric Dube
CEO | Chief Executive Officer | 51 | 19-01-03 |
Chris Cline
DFI | Director of Finance/CFO | 40 | 14-07-31 |
Jula Inrig
CTO | Chief Tech/Sci/R&D Officer | 49 | 22-01-03 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tim Coughlin
BRD | Director/Board Member | 57 | 15-03-30 |
Jeffrey Meckler
BRD | Director/Board Member | 57 | 14-10-07 |
Suzanne Bruhn
BRD | Director/Board Member | 60 | 20-04-07 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.15% | 0 M€ | 0.00% | - | |
0.12% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 6.26 | +1.62% | 767,565 |
24-05-02 | 6.16 | +2.67% | 1,290,027 |
24-05-01 | 6 | +8.50% | 1,882,726 |
24-04-30 | 5.53 | +1.28% | 1,315,865 |
24-04-29 | 5.46 | +3.80% | 1,582,375 |
Delayed Quote Nasdaq, May 03, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.37% | 476M | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |
- Stock Market
- Equities
- TVTX Stock